PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|October 24, 2013
SGS Life Science Services Opens Center of Excellence for Biophysical Analysis
Author(s)Pharmaceutical Technology Editors
SGS Life Science Services opens a Center of Excellence for Biophysical Analysis in the UK.
Advertisement
SGS Life Science Services has completed the development of a Center for Excellence for biophysical analysis of biopharmaceutical products in its SGS M-Scan facility in Wokingham, the United Kingdom.
The biophysical analysis group is lead by Dr.Iñigo Rodriguez-Mendieta, who along with his team, provides expertise in higher order structure analysis. The team can perform aggregation analysis, secondary/tertiary structural analysis, and thermal stability assessment and comparison. The new center complements the company's recent investment, announced in March 2013, to develop integrated formulation and stability testing services at the Wokingham facility, slated for completion in the fourth quarter 2013 and to be fully validated by early 2014.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement